Moderna

MRNA

Market cap $10.8B

Can you believe that Moderna (MRNA 5.52%) was once worth more than $195 billion in 2021? Back then, the business looked on track to be the next big healthcare company.

In the closing of the recent trading day, Moderna (MRNA) stood at $26.25, denoting a -1.83% move from the preceding trading day.

Moderna, Inc. faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited pipeline progress. Moderna's cost-cutting measures and cash reserves provide a buffer, but lack of new product launches and market competition challenge near-term growth. Oncology pipeline, especially mRNA-4157 and mRNA-4359, offers long-term promise, but regulatory and reimbursement hurdles remain substantial.

Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma will be presented at the 2025 European Society for Medical Oncology Congress.

mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory(CPI-R/R) melanoma patients will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025, in Berlin, Germany. mRNA-4359 is an investigational immune-evasion targeted cancer antigen therapy (CAT) that encodes epitopes of two common immune escape pathways, PD-L1 and IDO1, to elicit antigen-specific T cell responses that may directly kill tumor cells and deplete tumor suppressor cells.

In the closing of the recent trading day, Moderna (MRNA) stood at $27.92, denoting a +2.12% move from the preceding trading day.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Moderna (MRNA) concluded the recent trading session at $28.38, signifying a +2.83% move from its prior day's close.

Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.

From a technical perspective, Moderna (MRNA) is looking like an interesting pick, as it just reached a key level of support. MRNA recently overtook the 50-day moving average, and this suggests a short-term bullish trend.